tetano
Editor, Senior Moderator
J Infect Dis
. 2020 Aug 29;jiaa531.
doi: 10.1093/infdis/jiaa531. Online ahead of print.
A High Through-Put Assay For Circulating Antibodies Directed Against The S Protein Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2)
Svenja Weiss[SUP] 1 [/SUP], J?romine Klingler[SUP] 1 [/SUP], Catarina Hioe[SUP] 1 2 3 [/SUP], Fatima Amanat[SUP] 3 4 [/SUP], Ian Baine[SUP] 5 [/SUP], Suzanne Arinsburg[SUP] 5 [/SUP], Erna Milunka Kojic[SUP] 6 [/SUP], Jonathan Stoever[SUP] 7 [/SUP], Sean T H Liu[SUP] 3 [/SUP], Denise Jurczyszak[SUP] 3 [/SUP], Maria Bermudez-Gonzalez[SUP] 3 [/SUP], Viviana Simon[SUP] 1 3 8 [/SUP], Florian Krammer[SUP] 3 [/SUP], Susan Zolla-Pazner[SUP] 1 3 [/SUP]
Affiliations
Abstract
Over three million infections with the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) were confirmed globally by May, 2020. While PCR-based assays are used for diagnosis, high through-put, rapid serologic methods are needed. A Luminex binding assay was developed and used to assess simultaneously the presence of COVID-19-specific antibodies in human serum and plasma. Clear differentiation was achieved between specimens from infected and uninfected subjects, and a wide range of serum/plasma antibody levels were delineated in infected subjects. All 25 specimens from 18 COVID-19 patients were positive in the assays with both, the trimeric spike and the receptor-binding domain (RBD) proteins. None of the 13 specimens from uninfected subjects displayed antibodies to either antigen. There was a highly statistically significant difference between the antibody levels COVID-19-infected and -uninfected specimens (p<0.0001). This high through-put antibody assay is accurate, requires only 2.5 hours, and uses 5 nanograms of antigen per test.
Keywords: COVID-19; SARS-CoV-2; antibodies; antibody assay; coronavirus.
. 2020 Aug 29;jiaa531.
doi: 10.1093/infdis/jiaa531. Online ahead of print.
A High Through-Put Assay For Circulating Antibodies Directed Against The S Protein Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2)
Svenja Weiss[SUP] 1 [/SUP], J?romine Klingler[SUP] 1 [/SUP], Catarina Hioe[SUP] 1 2 3 [/SUP], Fatima Amanat[SUP] 3 4 [/SUP], Ian Baine[SUP] 5 [/SUP], Suzanne Arinsburg[SUP] 5 [/SUP], Erna Milunka Kojic[SUP] 6 [/SUP], Jonathan Stoever[SUP] 7 [/SUP], Sean T H Liu[SUP] 3 [/SUP], Denise Jurczyszak[SUP] 3 [/SUP], Maria Bermudez-Gonzalez[SUP] 3 [/SUP], Viviana Simon[SUP] 1 3 8 [/SUP], Florian Krammer[SUP] 3 [/SUP], Susan Zolla-Pazner[SUP] 1 3 [/SUP]
Affiliations
- PMID: 32860510
- DOI: 10.1093/infdis/jiaa531
Abstract
Over three million infections with the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) were confirmed globally by May, 2020. While PCR-based assays are used for diagnosis, high through-put, rapid serologic methods are needed. A Luminex binding assay was developed and used to assess simultaneously the presence of COVID-19-specific antibodies in human serum and plasma. Clear differentiation was achieved between specimens from infected and uninfected subjects, and a wide range of serum/plasma antibody levels were delineated in infected subjects. All 25 specimens from 18 COVID-19 patients were positive in the assays with both, the trimeric spike and the receptor-binding domain (RBD) proteins. None of the 13 specimens from uninfected subjects displayed antibodies to either antigen. There was a highly statistically significant difference between the antibody levels COVID-19-infected and -uninfected specimens (p<0.0001). This high through-put antibody assay is accurate, requires only 2.5 hours, and uses 5 nanograms of antigen per test.
Keywords: COVID-19; SARS-CoV-2; antibodies; antibody assay; coronavirus.